GCN2 regulates BMP signaling: consequence for PVOD pathobiology and therapeutic management

G. Manaud (Le Kremlin-Bicêtressis-Robinson, France), M. Lambert (Le Kremlin-Bicêtressis-Robinson, France), B. Soilih (Le Kremlin-Bicêtresis-Robinson, France), B. Girerd (Le Kremlin-Bicêtre, France), F. Soubrier (Paris, France), J. Bignard (Paris, France), O. Claude (Paris, France), F. Lecerf (Le Kremlin Bicêtre, France), M. Florio (Thousand Oaks, United States of America), B. Sun (Thousand Oaks, United States of America), S. Nadaud (Paris, France), S. Verleden (Leuven, Belgium), S. Rémy (Nantes, France), I. Anegon (Nantes, France), O. Mercier (Le Plessis-Robinson, France), E. Fadel (Le Plessis-Robinson, France), G. Simmoneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), F. Antigny (Le Kremlin-Bicêtre, France), F. Perros (Le Kremlin-Bicêtre, France)

Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Session: Pathophysiology of pulmonary hypertension
Session type: E-poster session
Number: 3551
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Manaud (Le Kremlin-Bicêtressis-Robinson, France), M. Lambert (Le Kremlin-Bicêtressis-Robinson, France), B. Soilih (Le Kremlin-Bicêtresis-Robinson, France), B. Girerd (Le Kremlin-Bicêtre, France), F. Soubrier (Paris, France), J. Bignard (Paris, France), O. Claude (Paris, France), F. Lecerf (Le Kremlin Bicêtre, France), M. Florio (Thousand Oaks, United States of America), B. Sun (Thousand Oaks, United States of America), S. Nadaud (Paris, France), S. Verleden (Leuven, Belgium), S. Rémy (Nantes, France), I. Anegon (Nantes, France), O. Mercier (Le Plessis-Robinson, France), E. Fadel (Le Plessis-Robinson, France), G. Simmoneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), D. Montani (Le Kremlin-Bicêtre, France), F. Antigny (Le Kremlin-Bicêtre, France), F. Perros (Le Kremlin-Bicêtre, France). GCN2 regulates BMP signaling: consequence for PVOD pathobiology and therapeutic management. 3551

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
mTOR signalling is an essential pathway for TGF-β1 induced collagen synthesis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro
Year: 2020




Hedgehog signalling crosstalks orchestrate human lung development
Source: Virtual Congress 2020 – Cellular stress in respiratory diseases
Year: 2020


BMP-Smad1 target gene Wnt inhibitory factor 1 (WIF1) coordinates BMP and Wnt signaling activities in regulating lung development in vivo
Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases
Year: 2010

Wnt and TGF-beta signaling in lung development
Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Year: 2009



NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD
Source: Eur Respir J 2016; 47: 254-263
Year: 2016



Increased pulmonary Wnt signaling in patients with sarcoidosis
Source: Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties
Year: 2007


PP208 – SRC family kinases modulate molecular pathways associated with mitochondrial dysfunction in idiopathic pulmonary fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021

Altered expression of the Smad signalling pathway: implications for COPD pathogenesis
Source: Eur Respir J 2006; 28: 533-541
Year: 2006



6-aminonicotinamide ameliorates pulmonary fibrosis by suppressing the TGF-beta1 activated Smad signalling pathway
Source: Virtual Congress 2020 – Translational therapeutic advances
Year: 2020


Decreased Wnt/β-catenin signaling in COPD: Possible involvement of Wnt antagonists
Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases
Year: 2012

The promise of mTOR signaling as a therapeutic target for IPF
Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
Year: 2020


The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020
Year: 2020



The oncogene c-Src plays a crucial role in the pathogenesis of COPD
Source: Annual Congress 2013 –Molecular biology: state-of-the-art 2013
Year: 2013


In addition to mTOR and JAK/STAT, NLRP3 inflammasome is another key pathway activated in sarcoidosis
Source: Eur Respir J, 55 (3) 2000149; 10.1183/13993003.00149-2020
Year: 2020



Hedgehog pathway activation is altered in COPD patients
Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Year: 2019


Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Source: Eur Respir J 2014; 44: 513-522
Year: 2014



Genetic targeting of the pulmonary epithelium: the role of TGF-b and wnt signaling in ontogeny of specialized cell types
Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Year: 2009